Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WOK vs AVR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Captures Overall Composite Edge (48.2 HOLD vs 25.6 SELL), While WOK Leads 4–2 on Growth & Valuation Pillars

AVR Overall Winner 6-Pillar Tally: WOK 4 – 2 AVR Matrix Metrics: WOK 2 – 6 AVR

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) captures the overall head-to-head institutional edge over WORK Medical Technology Group LTD Class A (WOK) on higher Unified Composite conviction (48.2/100 HOLD vs. 25.6/100 SELL) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while WOK wins 4–2 across the 6-pillar growth and valuation breakdown. WOK trades at $1.23 (N/M Forward P/E, -41.7% operating margin) versus AVR at $5.70 (N/M Forward P/E, -4880.4% operating margin).

  • Growth vs. Quality Trade-Off: AVR earns the overall head-to-head edge with a stronger Unified Composite Score (48.2/100 HOLD vs. WOK 25.6/100 SELL) and 1.56β · 77% Vol risk profile, whereas WOK leads top-line expansion (+19.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: WOK trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.1); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WOK vs AVR
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.70
+5.17% 1D
Market Cap $528.4M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.56β · 77% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 58.0 Fund 49.0 Flow 57.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 42
RSI-14: 42.5 · SMA20: $5.93 · SMA50: $6.90

6-Pillar Scorecard Institutional Category Breakdown (WOK 4 – 2 AVR)

Columns: Metric · WOK · AVR
1. Valuation Multiples WOK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.5x 133.9x
2. Growth & Scale AVR
Revenue Growth (YoY) +19.1% +21.0%
Earnings Growth (YoY) -95.0% +0.0%
TTM Revenue (USD) $11M $2.3M
Market Cap $5.4M $528.4M
3. Profitability & Quality WOK
Gross Margin 17.0% 75.8%
Operating Margin -41.7% -4880.4%
Net Profit Margin -41.9% 0.0%
Return on Equity (ROE) -19.2% -93.3%
4. Balance Sheet & Cash Flow WOK
Cash Generation (TTM) -$3.4M EBITDA -$94M
Cash Flow Margin -31.4% EBITDA Mgn N/A
Net Cash / Leverage $1855.16 Book/Sh · -19.2% ROE $216M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 58.5% (52nd %ile)
Put/Call OI Skew N/A 0.66x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat WOK
OpEx & R&D Intensity 58.7% of Rev ($6.3M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WOK (2) vs AVR (6)
Institutional Metric WOK AVR Criterion Row Edge
Market Capitalization
Scale
$5.4M $528.4M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+19.1% +21.0% Higher Growth AVR
Operating Margin (TTM)
Profitability
-41.7% -4880.4% Higher Margin WOK
Net Profit Margin
Profitability
-41.9% 0.0% Higher Margin AVR
Return on Equity (ROE)
Capital Efficiency
-19.2% -93.3% Higher ROE WOK
52-Week Range Position
Momentum
16% ($0–$7) 31% ($3–$11) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
38.49β · 153% Vol 1.56β · 77% Vol Lower Realized Risk AVR
Unified Institutional Score
Composite Signal
25.6 / 100 (SELL) 48.2 / 100 (HOLD) Higher Composite AVR
Trailing 12M Revenue (USD)
Operating Scale
$11M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
17.0% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.5x EV/Rev N/M PEG · 133.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) -$94M ($216M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon WOK +18.63 pp
WOK: +12.84% · AVR: -5.79%
3M Horizon AVR +3.59 pp
WOK: -44.09% · AVR: -40.5%
6M Horizon WOK +248.38 pp
WOK: +223.68% · AVR: -24.7%
1Y Horizon AVR +122.45 pp
WOK: -72.05% · AVR: +50.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WOK vs AVR. Trailing 12-month operating profitability (WOK -41.7% vs AVR -4880.4%) and valuation multiples (WOK N/M vs AVR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M
AVR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross Margin75.8%
Op. Margin-4880.4%
ROE / Fwd P/E-93.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVR BREAKDOWN
101d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 52nd %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $528.4M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WOK vs AVR Key Questions & Quantitative Answers

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) captures the overall head-to-head institutional edge over WORK Medical Technology Group LTD Class A (WOK) on higher Unified Composite conviction (48.2/100 HOLD vs. 25.6/100 SELL) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while WOK wins 4–2 across the 6-pillar growth and valuation breakdown. WOK trades at $1.23 (N/M Forward P/E, -41.7% operating margin) versus AVR at $5.70 (N/M Forward P/E, -4880.4% operating margin). Growth vs. Quality Trade-Off: AVR earns the overall head-to-head edge with a stronger Unified Composite Score (48.2/100 HOLD vs. WOK 25.6/100 SELL) and 1.56β · 77% Vol risk profile, whereas WOK leads top-line expansion (+19.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: WOK trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.1); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVR leads the Growth & Scale pillar: WOK posts +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin), compared with AVR at +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin). On trailing 12-month operating scale, WOK generates $11M in USD-normalized revenue versus $2.3M for AVR. In operating R&D and SG&A reinvestment, WOK deploys 58.7% of Rev ($6.3M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVR.

WOK screens cheaper on headline valuation multiples. WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin), whereas AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 133.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WOK (-19.2% ROE) versus AVR (-93.3% ROE) capital efficiency.

In options market volatility and institutional positioning, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk). By comparison, AVR carries 58.5% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

WORK Medical Technology Group LTD Class A Ordinary Shares (WOK) Research Suite

Anteris Technologies Global Corp. Common Stock (AVR) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.